ICM-VAL D'AURELLE
Desconocido
MR O MICS: Unravelling Tumour Biology In Ovarian Cancer With Precision Imaging
INSTITUT REGIONAL DU CANCER DE MONTPELLIER
tramitó un
HORIZON EUROPE:
ERC-2022-STG
High-grade serous ovarian cancer (HGSOC) is the most common subtype of ovarian cancer. The early rapid onset of chemoresistance poses a majo...
2023-08-13 - 2028-08-31 | Financiado
2023-08-13 - 2028-08-31 | Financiado
LIMA: Liquid biopsies and Imaging for improved cancer care
INSTITUT REGIONAL DU CANCER DE MONTPELLIER
participó en un
H2020:
H2020-SC1-2016-2017
LIMA’s overall objective is to develop and validate technologies and tools to include liquid biopsies in the clinical workflow, aiming at in...
2017-11-21 - 2022-06-30 | Financiado
2017-11-21 - 2022-06-30 | Financiado
REQUITE: Validating predictive models of radiotherapy toxicity to improve quality of life and reduce side eff...
INSTITUT REGIONAL DU CANCER DE MONTPELLIER
participó en un
FP7:
Long-term side-effects of radiotherapy impact on the quality-of-life (QoL) of cancer survivors. These side-effects could be reduced if predi...
Financiado
Financiado
* No se disponen de datos de la empresa actual.